Hybrid closed-loop system boosts time in range for young children with type 1 diabetes

In a recent study, researchers demonstrate that a hybrid closed-loop (HCL) system, a type of artificial pancreas, is capable of significantly increasing time in range for young children with type 1 diabetes.

Results reveal that the HCL system, when compared to traditional diabetes management approaches, enabled participants to spend a significantly greater amount of time in the optimal blood sugar range.

For the study, researchers enrolled 17 children aged 6 to 13 with type 1 diabetes. Participants were randomly assigned to use either an HCL system or traditional diabetes management for a period of four weeks.

Results show that the HCL system enabled participants to spend more than 65% of the time in the optimal blood sugar range. This was significantly higher than the amount of time in the range recorded for the traditional diabetes management group, which was less than 45%.

The findings suggest that the HCL system is a promising intervention for young children with type 1 diabetes, and could result in improved glycemic control and reduced risk of long-term complications.

A hybrid closed-loop system is a type of artificial pancreas that automates the delivery of insulin when glucose levels exceed preset thresholds. In a recent trial, researchers sought to evaluate the efficacy of an HCL system in improving glycemic control among young children with type 1 diabetes.

The study enrolled 17 participants aged between 6 and 13 with type 1 diabetes, who were randomly assigned to either an HCL system or traditional diabetes management approach. Results indicate that the HCL system was effective in significantly increasing the proportion of time spent in the optimal blood sugar range. Specifically, participants in the HCL system group spent more than 65% of the time in the optimal range, compared to less than 45% for the traditional diabetes management group.

The findings demonstrate that the HCL system is a promising intervention for young children with type 1 diabetes, and could result in improved glycemic control and reduced risk of long-term complications.